• Combination NOX66 + 177Lutetium-PSMA radionuclide therapy in late-stage prostate cancer
• Treatment well tolerated in first cohort of 4 patients; second cohort now to start treatment
• Promising clinical response in 3 of 4 patients on lowest NOX66 dosage.
Sydney, 17 April 2018: Noxopharm (ASX:NOX) is pleased to announce that the LUPIN clinical study being conducted at St Vincent’s Hospital in Sydney has received approval to enrol the second cohort of patients following a safety review of the first cohort that showed absence of any adverse events.
For further information please download PDF attached:
Download this document
